• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » GSK CEO predicts R&D success

GSK CEO predicts R&D success

July 29, 2011
CenterWatch Staff

GlaxoSmithKline CEO Andrew Witty said the pharmaceutical industry would contract in coming years and that the survivors would be those companies that solved the "equation" of how to squeeze the most profit from every dollar spent on R&D, according to the Philadelphia Inquirer.

"The market is signaling that it wants less—in total—spent on R&D, so the total amount of R&D will come down," Witty said. "That is what it is signaling through pricing and challenges it throws up in front of drug companies to get products to market.”

"Inevitably, you are now seeing, for the first time in history, a reduction in the total amount of industrial R&D done in the pharmaceutical space. But within that, there is clearly space for winners and losers,” continued Witty.

"There is tremendous opportunity for the few companies who solve the R&D equation," Witty said. "It's the companies who deliver multiple new products, not one or two, that address material clinical needs of patients and address the economic needs of the payers—so they are fairly priced.”

"My belief is that five to seven years from today, you'll see a significant number of companies retreat from the pharmaceutical space, one way or another. I think you'll see a few companies solve the problem, and I'm determined that GSK is going to be one of them."

Glaxo reported profits in the second quarter due to better-than-expected cost savings in its restructuring program and in tax changes related to its changing geography. Witty began restructuring the company four years ago, with part of the emphasis on emerging markets. He said 37% of sales were outside the U.S. and Europe, but the company also has facilities in India, China and Singapore.

Despite a 4% drop in revenue, the second-quarter profit was $1.8 billion, compared with a loss of $499 million in the second quarter of 2010.

Witty's restructuring included layoffs in the U.S. sales force. Another piece is moving the 1,300 employees to a new facility under construction. The 15½-year lease is a commitment to the city, but Glaxo also hopes to save money through less unused space.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing